<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97500">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957657</url>
  </required_header>
  <id_info>
    <org_study_id>1241.32</org_study_id>
    <secondary_id>2013-001075-21</secondary_id>
    <nct_id>NCT01957657</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate the effect of different degrees of renal
      impairment on the pharmacokinetics and safety of the combination of BI 207127 and
      faldaprevir after 3 days of dosing (BI 207127 bid, faldaprevir qd) and a single dose of BI
      207127 and faldaprevir on day 4.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 207127 in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of BI 207127 in plasma)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (%) of subjects with drug-related adverse events</measure>
    <time_frame>up to 18 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (CD 6168) in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (BI 208333) in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites (CD 6168 acylglucuronide) in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 207127 metabolites faldaprevir in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 207127 metabolites (CD 6168) in plasma)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 207127 metabolites (BI 208333) in plasma)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 207127 metabolites (CD 6168 acylglucuronide) in plasma)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 207127 metabolites faldaprevir in plasma)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal function group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal function group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal function group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with servere renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Healthy volunteers group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Healthy volunteers group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>faldaprevir</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Renal function group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy volunteers (males and females) or patients with impaired renal function
             (estimated glomerular filtration rate (eGFR) between 89 and 15) in relatively good
             health as determined by past medical history, physical examination, vital signs, ECG
             and laboratory assessments (aside from abnormalities specific for renal impairment)

          -  Age from 18 to 79 years

          -  Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

          -  Any relevant deviation from healthy conditions for healthy volunteers

          -  Subjects with significant diseases other than renal impairment will be excluded. A
             significant disease is defined as a disease which in the opinion of the investigator:

               -  put the patient at risk because of participation in the study

               -  may influence the results of the study

               -  may influence the patients ability to participate in the study

               -  is not in a stable condition

          -  Diabetic or hypertensive patients can be entered in this trial if the disease is not
             significant according to these criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.32.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>October 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
